Ibrutinib-associated osteonecrosis of the jaw
Ibrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL). Ibrutinib has well-described side effects that limits its use such as, increased risk of atrial fibrillation, hypertensio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024000748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|